Vizgen Raises $37M in Series B Financing

23 Apr, 2021

Vizgen Raises $37M in Series B Financing
Photo by Clément Hélardot on Unsplash

– Vizgen from Cambridge, MA develops genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context.
– Series B $37m round was led by Novalis LifeSciences LLC and current investor Northpond Ventures with participation from new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund, and current investors ARCH Venture Partners and David Walt, Ph.D., Professor at Harvard Medical School, Core Faculty at the Wyss Institute, and co-founder of Vizgen.
– The company intends to use the funds to accelerate growth and infrastructure expansion leading up to full commercial launch.

Biotechnology North America
Crunchbase icon

Content report

The following text will be sent to our editors: